Last reviewed · How we verify

NCT04361487: NOVOSTITCH PRO

Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears

Terminated Results posted Last updated 24 February 2026
What this trial tests

trial testing NOVOSTITCH™ PRO Meniscal Repair System in Meniscus Tear in 33 participants. Terminated before completion.

Timeline
13 November 2020
Primary endpoint
25 April 2024
25 April 2024

Quick facts

Lead sponsorSmith & Nephew, Inc.
StatusTerminated
Study typeOBSERVATIONAL
Enrollment33
Start date13 November 2020
Primary completion25 April 2024
Estimated completion25 April 2024
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Smith & Nephew, Inc. — full company profile →

Who can join

Adults 18 to 70, any sex, with Meniscus Tear or Retention; Meniscus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Rate of Freedom From Reoperation at 12 Months After Surgery Primary · 12 months

Percentage of participants with freedom from reoperation due to meniscal repair failure at 12 months after surgery (i.e., no re-operation required). Freedom from reoperation was defined as no re-operation required due to meniscal repair failure for any reason.

GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System10088.06 – 100
Rate of Freedom From Reoperation at 6 & 24 Months After Surgery Secondary · 6 months, 24 months

Percentage of participants with freedom from reoperation due to meniscal repair failure at 6 months \& 24 months after surgery (i.e., no re-operation required). Freedom from reoperation was defined as no re-operation required due to meniscal repair failure for any reason.

6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System10088.43 – 100
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System10086.28 – 100
Structural Integrity of Meniscus Assessed by MRI Secondary · Baseline, 12 months, and 24 months

Structural integrity of the meniscus was identified using Magnetic Resonance Imaging (MRI) by the results of the Meniscal Signal Index Meniscus grading. Participants were categorized using the following grading: * Grade 0: Low signal intensity indicative of a normal meniscus. * Grade 1: Irregularly marginated elevated signal with globular shape, suggestive of early meniscal degeneration. * Grade 2: Linear elevated signal (i.e. confirmed fluid signal) not extending into the tibial or femoral articular surface. * Grade 3: Linear elevated signal (i.e. confirmed fluid signal) extending into the t

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System31
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System2
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System26
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System1
NOVOSTITCH™ PRO Meniscal Repair System0
NOVOSTITCH™ PRO Meniscal Repair System24
Change in Tibiofemoral Joint Space Narrowing (JSN) in Medial Compartment From Baseline to 24 Months Secondary · Baseline to 24 months

Change in Tibiofemoral Joint Space Narrowing (JSN) in the medial compartment was measured in millimeters (mm) as assessed by x-rays.

GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System-0.3± 0.8
Change in Tibiofemoral Joint Space Narrowing (JSN) in Lateral Compartment From Baseline to 24 Months Secondary · Baseline to 24 months

Change in Tibiofemoral Joint Space Narrowing (JSN) in the lateral compartment was measured in millimeters (mm) as assessed by x-rays.

GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System-0.2± 0.7
In-Office Needle Endoscopy at 6 Months Secondary · 6 months

In-office needle endoscopy is a minimally invasive procedure in which a needle-sized camera is inserted into tissue for observation and/or biopsy purposes. For this study, a needle-sized endoscopy was inserted to record video and images of the meniscal repair site and visually assess healing. Healing by participant was categorized as: * Healed * Incompletely Healed * Failure

GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System6
NOVOSTITCH™ PRO Meniscal Repair System3
NOVOSTITCH™ PRO Meniscal Repair System0
Patient Reported Outcome (PRO): International Knee Documentation Committee (IKDC) Subjective Score Secondary · Baseline, 6 months, 12 months, and 24 months

The International Knee Documentation Committee (IKDC) Subjective score was developed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment, including patients with meniscal injuries. Possible scores range from 0-100, where 100 indicated the highest level of function and lowest level of symptoms (i.e., better outcome), and 0 indicated the lowest level of function or highest level of symptoms (i.e., worse outcome).

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System49.2± 14.4
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System70.2± 14.5
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System76.8± 15.7
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System84.1± 12.7
Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) - Symptoms Score Secondary · Baseline, 6 months, 12 months, and 24 months

The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five patient-relevant subscales with each scored separately. The subscales are Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items). A Likert scale is used for each subscale with five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale with 0 representing extreme knee problems (i.e., worse outcome) and 100

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System71.3± 16.0
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System81.5± 13.1
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System85.5± 14.5
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System87.5± 12.9
Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Score Secondary · Baseline, 6 months, 12 months, and 24 months

The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five patient-relevant subscales with each scored separately. The subscales are Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items). A Likert scale is used for each subscale with five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale with 0 representing extreme knee problems (i.e., worse outcome) and 100

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System69.1± 15.5
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System83.2± 11.8
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System86.6± 12.5
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System92.0± 9.0
Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activities of Daily Life Score Secondary · Baseline, 6 months, 12 months, and 24 months

The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five patient-relevant subscales with each scored separately. The subscales are Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items). A Likert scale is used for each subscale with five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale with 0 representing extreme knee problems (i.e., worse outcome) and 100

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System74.9± 15.5
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System91.2± 8.4
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System92.3± 11.9
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System95.2± 7.2
Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sport Score Secondary · Baseline, 6 months, 12 months, and 24 months

The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five patient-relevant subscales with each scored separately. The subscales are Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items). A Likert scale is used for each subscale with five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale with 0 representing extreme knee problems (i.e., worse outcome) and 100

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System42.1± 22.6
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System68.1± 19.2
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System77.7± 17.5
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System86.5± 14.6
Patient Reported Outcome (PRO): Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of Life Score Secondary · Baseline, 6 months, 12 months, and 24 months

The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five patient-relevant subscales with each scored separately. The subscales are Pain (9 items), Symptoms (7 items), ADL function (17 items), Sport and Recreation Function (5 items), and Quality of Life (4 items). A Likert scale is used for each subscale with five possible answer options scored from 0 (no problems) to 4 (extreme problems). Each of the 5 scores is calculated as the sum of the items included and then each score is transformed to a 0-100 scale with 0 representing extreme knee problems (i.e., worse outcome) and 100

Baseline
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System30.0± 17.0
6 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System57.1± 22.3
12 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System67.7± 20.5
24 months
GroupValue95% CI
NOVOSTITCH™ PRO Meniscal Repair System75.5± 17.3

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected during surgery until early termination of the study, up to 2 years.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

NOVOSTITCH™ PRO Meniscal Repair System
Serious: 6/33 (18%)
Deaths: 0/33

Serious adverse events (5 terms)

ReactionSystemNOVOSTITCH™ PRO Meniscal R…
MENSTRUAL IRREGULARITIESReproductive system and breast disorders
APNEARespiratory, thoracic and mediastinal disorders
BONE FRACTURE(S)Musculoskeletal and connective tissue disorders
LIMB FRACTUREMusculoskeletal and connective tissue disorders
PAINGeneral disorders
Other adverse events (30 terms — click to expand)

ReactionSystemNOVOSTITCH™ PRO Meniscal R…
PAINGeneral disorders
UNSPECIFIED RESPIRATORY PROBLEMRespiratory, thoracic and mediastinal disorders
CHEST PAINGeneral disorders
HYPERSENSITIVITY/ALLERGIC REACTIONImmune system disorders
UNSPECIFIED VASCULAR PROBLEMVascular disorders
RESPIRATORY TRACT INFECTIONRespiratory, thoracic and mediastinal disorders
CORNEAL ABRASIONEye disorders
UNSPECIFIED EAR OR LABYRINTH PROBLEMEar and labyrinth disorders
GASTRITISGastrointestinal disorders
UNSPECIFIED GASTROINTESTINAL PROBLEMGastrointestinal disorders
VITAMIN DEFICIENCYEndocrine disorders
URINARY TRACT INFECTIONRenal and urinary disorders
BREAST MASSReproductive system and breast disorders
CONGENITAL DEFECT/DEFORMITYPregnancy, puerperium and perinatal conditions
ARTHRITISMusculoskeletal and connective tissue disorders
DAMAGE TO LIGAMENT(S)Musculoskeletal and connective tissue disorders
LOSS OF RANGE OF MOTIONMusculoskeletal and connective tissue disorders
MUSCLE WEAKNESSMusculoskeletal and connective tissue disorders
BURNING SENSATIONSkin and subcutaneous tissue disorders
SKIN DISCOLORATIONSkin and subcutaneous tissue disorders
SKIN DISORDERSSkin and subcutaneous tissue disorders
URINARY TRACT INFECTIONInfections and infestations
BACTERIAL INFECTIONInfections and infestations
TOXEMIAInfections and infestations
FUNGAL INFECTIONInfections and infestations
DAMAGE TO LIGAMENT(S)Injury, poisoning and procedural complications
BRUISE/CONTUSIONInjury, poisoning and procedural complications
IMPLANT PAINGeneral disorders
HEADACHEGeneral disorders
INFLAMMATIONGeneral disorders

Most-reported serious reactions: MENSTRUAL IRREGULARITIES, APNEA, BONE FRACTURE(S), LIMB FRACTURE, PAIN.

Data from ClinicalTrials.gov NCT04361487 adverse events section.

Sponsor's own description

The purpose of this study is to understand the benefits and safety of the NOVOSTITCH PRO Meniscal Repair (NOVOSTITCH PRO) system. The meniscus is a tissue in the knee joint. The NOVOSTITCH PRO is used during surgery to fix meniscus tears in the knee. It is unknown whether fixing a meniscus tear is better than the approach of removing the tear. Data will be collected on participants prior to surgery, at surgery, and for 2 years after surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Meniscus Tear

Currently open trials in the same condition.

Other Smith & Nephew, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04361487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing